36476-82-1

Basic information

• Product Name: 1-(DIPHENYLMETHYL)-3-METHOXYAZETIDINE
• Synonyms: 1-(DIPHENYLMETHYL)-3-METHOXYAZETIDINE;1-Benzhydryl-3-methoxy-azetidine;Azetidine, 1-(diphenylMethyl)-3-Methoxy-
• CAS NO: 36476-82-1
• Molecular Formula: C₁₇H₁₉NO
• Molecular Weight: 253.34
• Mol File: 36476-82-1.mol

Chemical Properties

• Boiling Point: 335.1 °C at 760 mmHg
• Flash Point: 99 °C
• Appearance: /
• Density: 1.11 g/cm³
• Storage Temp.: 2-8°C
• PKA: 6.48±0.10(Predicted)
• CAS DataBase Reference: 1-(DIPHENYLMETHYL)-3-METHOXYAZETIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(DIPHENYLMETHYL)-3-METHOXYAZETIDINE(36476-82-1)
• EPA Substance Registry System: 1-(DIPHENYLMETHYL)-3-METHOXYAZETIDINE(36476-82-1)

Safety Data

• Hazardous Substances Data: 36476-82-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Synthesis:
1-(Diphenylmethyl)-3-methoxyazetidine is utilized as a key intermediate in the research and synthesis of pharmaceuticals. Its unique structure allows it to be a versatile building block for the development of new drugs, particularly in the field of medicinal chemistry.
Used in Organic Chemistry:
In the field of organic chemistry, 1-(Diphenylmethyl)-3-methoxyazetidine serves as a valuable compound for studying the reactivity and behavior of azetidine derivatives. Its diphenylmethyl and methoxy groups can be manipulated to explore various chemical reactions and transformations, contributing to the understanding of azetidine chemistry.
Used in Material Science:
1-(Diphenylmethyl)-3-methoxyazetidine may also find applications in material science, where its unique properties can be leveraged to develop new materials with specific characteristics. For instance, its solubility and reactivity can be exploited to create novel polymers or other materials with tailored properties for various applications.

Upstream product

• 90604-02-7 1-(diphenylmethyl)-3-azetidinol hydrochloride 
• 776-74-9 Bromodiphenylmethane 
• 91-00-9 Benzhydrylamine 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 
• 74-88-4 methyl iodide 

Downstream Products

• 1252779-85-3 1-[4-(1-benzhydrylazetidin-3-yl)piperazin-1-yl]-2,2,2-trifluoroethanone 
• 110925-17-2 3-methoxyazetidine 

Relevant articles and documents

Hydrogen Bonding Phase-Transfer Catalysis with Ionic Reactants: Enantioselective Synthesis of γ-Fluoroamines

Ammonium salts are used as phase-Transfer catalysts for fluorination with alkali metal fluorides. We now demonstrate that these organic salts, specifically azetidinium triflates, are suitable substrates for enantioselective ring opening with CsF and a chiral bis-urea catalyst. This process, which highlights the ability of hydrogen bonding phase-Transfer catalysts to couple two ionic reactants, affords enantioenriched γ-fluoroamines in high yields. Mechanistic studies underline the role of the catalyst for phase-Transfer, and computed transition state structures account for the enantioconvergence observed for mixtures of achiral azetidinium diastereomers. The N-substituents in the electrophile influence the reactivity, but the configuration at nitrogen is unimportant for the enantioselectivity.

Counterion-Induced Asymmetric Control in Ring-Opening of Azetidiniums: Facile Access to Chiral Amines

Counterion-induced stereocontrol is a powerful tool in organic synthesis. However, such enantiocontrol on tetrahedral ammonium cations remains challenging. Described here is the first example of using chiral anion phase-transfer catalysis to achieve intermolecular ring-opening of azetidiniums with excellent enantioselectivity (up to 97 % ee). Precise control over the formation and reaction of the chiral ion pair as well as inhibition of the background reaction by the biphasic system is key to the success of the reaction.

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/ or the mTOR pathway.

ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS

The present invention provides heterocyclic compounds of the following formula (I) : or pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof useful as antibacterial agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

PYRAZOLE DERIVATIVES

A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

PYRAZINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF

A pyrazine derivative of the following formula (I): or a salt thereof. The pyrazine compound (I) and a salt thereof of the present invention are adenosine antagonists and are useful for the prevention and/or treatment of depression, dementia (e.g. Alzheimer’s disease, cerebrovascular dementia, dementia accompanying Parkinson’s, disease, etc.), Parkinson’s disease, anxiety, pain, cerebrovascular disease (e.g. stroke), etc.), heart failure and the like.

PYRAZOLE DERIVATIVE

Not available

Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use

The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

BENZOFUSED HETEROARYL AMIDE DERIVATIVES OF THIENOPYRIDINES USEFUL AS THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND METHODS FOR THEIR USE

The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

Phenyloxazolidinone antimicrobials

The present invention relates to antimicrobial phenyloxazolidinone compounds having a pyrrolidinyl or azetidinyl moiety.